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Summary
Background Dose intensiﬁ cation with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone 
(CHOP) every 2 weeks improves outcomes in patients older than 60 years with diﬀ use large B-cell lymphoma 
compared with CHOP every 3 weeks. We investigated whether this survival beneﬁ t from dose intensiﬁ cation persists 
in the presence of rituximab (R-CHOP) in all age groups.
Methods Patients (aged ≥18 years) with previously untreated bulky stage IA to stage IV diﬀ use large B-cell lymphoma in 
119 centres in the UK were randomly assigned centrally in a one-to-one ratio, using minimisation, to receive six cycles of 
R-CHOP every 14 days plus two cycles of rituximab (R-CHOP-14) or eight cycles of R-CHOP every 21 days (R-CHOP-21). 
R-CHOP-21 was intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1·4 mg/m² (maximum 
dose 2 mg), and rituximab 375 mg/m² on day 1, and oral prednisolone 40 mg/m² on days 1–5, administered every 21 days 
for a total of eight cycles. R-CHOP-14 was intravenous cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 
2 mg, rituximab 375 mg/m² on day 1, and oral prednisolone 100 mg on days 1–5, administered every 14 days for six 
cycles, followed by two further infusions of rituximab 375 mg/m² on day 1 every 14 days. The trial was not masked. The 
primary outcome was overall survival (OS). This study is registered, number ISCRTN 16017947.
Findings 1080 patients were assigned to R-CHOP-21 (n=540) and R-CHOP-14 (n=540). With a median follow-up of 
46 months (IQR 35–57), 2-year OS was 82·7% (79·5–85·9) in the R-CHOP-14 group and 80·8% (77·5–84·2) in the 
R-CHOP-21 (standard) group (hazard ratio 0·90, 95% CI 0·70–1·15; p=0·3763). No signiﬁ cant improvement was noted 
in 2-year progression-free survival (R-CHOP-14 75·4%, 71·8–79·1, and R-CHOP-21 74·8%, 71·0–78·4; 0·94, 0·76–1·17; 
p=0·5907). High international prognostic index, poor-prognosis molecular characteristics, and cell of origin were not 
predictive for beneﬁ t from either schedule. Grade 3 or 4 neutropenia was higher in the R-CHOP-21 group (318 [60%] of 
534 vs 167 [31%] of 534), with no prophylactic use of recombinant human granulocyte-colony stimulating factor 
mandated in this group, whereas grade 3 or 4 thrombo cytopenia was higher with R-CHOP-14 (50 [9%] vs 28 [5%]); other 
frequent grade 3 or 4 adverse events were febrile neutropenia (58 [11%] vs 28 [5%]) and infection (125 [23%] vs 96 [18%]). 
Frequencies of non-haematological adverse events were similar in the R-CHOP-21 and R-CHOP-14 groups.
Interpretation R-CHOP-14 is not superior to R-CHOP-21 chemotherapy for previously untreated diﬀ use large B-cell 
lymphoma; therefore, R-CHOP-21 remains the standard ﬁ rst-line treatment in patients with this haematological 
malignancy. No molecular or clinical subgroup beneﬁ ted from dose intensiﬁ cation in this study.
Funding Chugai Pharmaceutical, Cancer Research UK, National Institute for Health Research Biomedical Research 
Centres scheme at both University College London and the Royal Marsden NHS Foundation Trust, and Institute of 
Cancer Research.
Introduction
Diﬀ use large B-cell lymphoma represents more than 
30% of all diagnoses of non-Hodgkin lymphoma.1 
Combination chemotherapy with cyclophosphamide, 
doxorubicin, vin cristine, and prednisolone (CHOP) was 
established as a standard treatment almost 40 years ago. 
Intensive regi mens have not consistently improved 
outcomes compared with CHOP every 3 weeks 
(CHOP-21), includ ing the use of high-dose treatment 
plus autologous stem-cell transplant.2,3 However, in 
2004, the results of the German High-Grade Lymphoma 
Study Group phase 3 study showed superior overall 
survival (OS) with six cycles of CHOP every 14 days 
(CHOP-14) compared with six cycles of CHOP-21 in 
patients aged 60 years and older,4 although these results 
were not replicated in a smaller Japanese study of eight 
cycles of CHOP-14 versus CHOP-21 in patients with 
aggressive non-Hodgkin lymphoma, only 58% of whom 
had diﬀ use large B-cell lymph oma.5 Incorporation of 
etoposide into CHOP improved response rates and 
event-free survival in young patients, but did not aﬀ ect 
overall survival in any age group.4,6 An alternative 
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dose-intense regimen of cyclophosphamide, vindesine, 
bleomycin, and prednisolone followed by high-dose 
metho trexate, ifosfamide, and cytarabine (ACVBP) also 
improved survival compared with standard CHOP-21 in 
both localised disease and poor-prognosis aggressive 
non-Hodgkin lymphoma but the results did not 
change clinical practice, probably due to toxicity of the 
polydrug com bination.7,8
Concurrent with these results, rituximab, an anti-
CD20 monoclonal antibody, combined with CHOP-21 
improved cure rates by 10–15% compared with 
CHOP-21 alone without serious additional toxicity in 
the pivotal phase 3 Groupe d’Etude des Lymphomes de 
l’Adulte (GELA) trial;9,10 the results were conﬁ rmed in a 
sub sequent US intergroup study.11 Rituximab also 
added beneﬁ t to CHOP-14 (R-CHOP-14) in patients 
older than 60 years in the RICOVER-60 trial,12 and in 
young patients (aged 18–60 years) with a good prognosis 
in the MiNT study.13
However, whether the improved survival reported with 
CHOP-14 by the German group4 was still evident in 
patients receiving rituximab remained uncertain. There-
fore, in 2005, the UK National Cancer Research Institute 
Lymphoma Clinical Study Group commenced a large, 
randomised study of all patients older than 18 years with 
previously untreated diﬀ use large B-cell lymphoma to 
compare CHOP-14 with CHOP-21 in patients receiving 
rituximab. This phase 3, open-label randomised study 
was designed to detect superior OS of the dose-intense 
regimen R-CHOP-14 versus standard R-CHOP-21 in 
patients of all age groups and all risk strata.
Methods
Patients
In this phase 3 study, patients with diﬀ use large B-cell 
lymphoma were enrolled in 119 centres in the UK. 
Eligible patients were aged 18 years and older with 
previously untreated, histologically conﬁ rmed, diﬀ use 
large B-cell lymphoma according to the WHO classiﬁ -
cation.14 Patients were required to have Ann Arbor bulky 
stage IA (tumour mass diameter >10 cm) or stage IB–IV 
disease, a good performance status (WHO grade 0–2), 
adequate cardiac, renal, hepatic, and haematological 
func tion (initial neutrophil count >1·5 × 10⁹ per L, initial 
platelet count >100 × 10⁹ per L unless the abnormality was 
caused by lymph oma rather than another disease in 
which case the patient was eligible). Patients with T-cell 
lymphomas, transformed follicular lymphoma, or a 
history of indolent lymphoma were excluded. However, 
patients with previously undiag nosed concurrent small-
cell inﬁ ltration in bone marrow or lymph node were 
eligible. Patients with CNS involvement, positive serology 
for HIV, hepatitis B or hepatitis C virus, a history of heart 
failure or uncontrolled angina pectoris, active malignancy 
in the preceding 10 years, or other illnesses precluding 
administration of study treatment were ineligible.
The trial was overseen by a trial steering committee 
and an independent data monitoring committee. The 
protocol was approved by the UK Medicines and 
Healthcare products Regulatory Agency and Hull and 
East Riding Research Ethics Committee, and done in 
accordance with the Declaration of Helsinki and the 
European Union Clinical Trials Directive 2001/20/EC. 
Patients provided written informed consent.
Randomisation and masking
Randomisation was done centrally by the Cancer 
Research UK and University College London Cancer 
Trials Centre, London, UK, using a minimisation pro-
cedure, stratiﬁ ed for international prognostic index 
(IPI) and centre. Patients were allocated in a one-to-one 
ratio to R-CHOP-21 or R-CHOP-14 regimens. The trial 
was not masked.
Procedures
The R-CHOP-21 regimen was based on the original doses 
used by the GELA group9 and consisted of intravenous 
cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², 
Figure 1: Trial proﬁ le
R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days. 
R-CHOP-14=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 14 days. 
LVEF=left ventricular ejection fraction. *Includes 35 people who did not have an end-of-treatment scan and 
therefore were not assessable for end-of-treatment response. †Includes 34 people  who did not have an 
end-of-treatment scan and therefore were not assessable for end-of-treatment response.
1080 patients randomly assigned
540 assigned to R-CHOP-21 540 assigned to R-CHOP-14
4 excluded
 1 incorrect diagnosis (chronic 
  lymphocytic leukaemia)
 1 coexisting illnesses
 2 died before treatment
535 commenced 
 R-CHOP-21*
536 commenced 
 R-CHOP-14†
60 did not complete treatment†
 5 progressive disease
 22 toxicity
 12 deaths
 4 incorrect diagnosis
 8 other disorders
 5 patient’s or clinician’s decision
 2 achieved maximum response
 2 other
113 did not complete treatment*
 17 progressive disease
 38 had toxicity
 11 deaths
 5 incorrect diagnosis
 8 other disorders
 17 patient’s or clinician’s decision
 8 achieved maximum response
 9 other
500 assessed for end-of-
 treatment response
502 assessed for end-of-
 treatment response
422 completed R-CHOP-21* 476 completed R-CHOP-14†
540 analysed 540 analysed
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 1 LVEF 40–50%
 2 died before treatment
 1 incorrect diagnosis (Burkitt‘s 
  lymphoma)
 1 withdrew consent
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vincristine 1·4 mg/m² (maximum dose 2 mg), rituximab 
375 mg/m² on day 1, and oral prednisolone 40 mg/m² on 
days 1–5, administered every 21 days for a total of eight 
cycles. R-CHOP-14, designed by the German High Grade 
Lymphoma Study Group,4 consisted of intravenous 
cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², 
vincristine 2 mg, rituximab 375 mg/m² on day 1, and oral 
prednisolone 100 mg on days 1–5, administered every 
14 days for six cycles followed by two further infusions 
of rituximab 375 mg/m² on day 1 every 14 days. 
The recombinant human granulocyte-colony stimu-
lating factor (G-CSF) lenograstim was administered on 
days 4–12 of each cycle to patients randomly assigned to 
R-CHOP-14 whereas use of G-CSF for patients receiving 
R-CHOP-21 was at the discretion of the investigators. All 
patients received allopurinol 300 mg/day for the ﬁ rst cycle 
and co-trimoxazole 480 mg twice daily for 3 days per week 
until 2 weeks after the end of treatment. Other suppor tive 
medications were given according to local proto cols. 
Prophylaxis for CNS relapse was at the dis cretion of the 
investigators; however, the recom mendation was that 
patients with large-cell lymphoma involvement of the bone 
marrow, peripheral blood, nasal or paranasal sinuses, 
orbit, and testis receive 12·5 mg intrathecal methotrexate 
for the ﬁ rst three cycles of treatment, administered as per 
local guidelines. Consoli dation radiotherapy was also 
permitted at the discretion of the investigators.
Patients were assessed before treatment; at each atten-
dance for treatment; and then after treatment every 
3 months until 1 year, then every 6 months until 2 years, 
and thereafter every year. Reports by clinicians included 
details of treatment and adverse eﬀ ects, performance 
status, and results of blood counts and other relevant 
tests. CT scans of the chest, abdomen, pelvis, with or 
without neck were done at baseline, after four cycles of 
chemotherapy, at the end of treatment, and at 3 months 
and 12 months after completion of treatment. In the 
event of clinical suspicion of relapse, additional imaging 
was done. ¹⁸F-ﬂ uorodeoxyglucose (¹⁸F-FDG) PET scans 
were not mandated and therefore no PET data were 
gathered as part of the main study.
Central pathology review was done by an expert 
haematopathologist (AJ). A full immunohistochemical 
panel was done for all available specimens and included 
CD20, CD79a, P53 expression, and the proliferation 
index (MIB1). Molecular phenotype (germinal centre vs 
non-germinal centre) was determined using the Hans 
criteria.15 Fluorescence in-situ hybridisation (FISH) was 
done according to reported methods16 to detect MYC, 
BCL6, and BCL2 rearrangements.
Statistical analysis
The primary outcome was OS. The secondary outcomes 
were progression-free survival (PFS), toxicity, and response 
rate. The method of analysis was intention to treat.
The sample size was based on an estimated 2-year OS 
of 70% in the R-CHOP-21 group; the aim in the trial 
R-CHOP-21 (n=540) R-CHOP-14 (n=540)
Age (years; median, range)
Median (years) 61 (19–88) 61 (19–85)
≤60 239 (44%) 237 (44%)
>60 301 (56%) 303 (56%)
Sex
Male 293 (54%) 289 (54%)
Female 247 (46%) 251 (46%)
WHO performance status
0 258 (48%) 286 (53%)
1 210 (39%) 182 (34%)
2 72 (13%) 72 (13%)
Stage
Bulky IA 20 (4%) 26 (5%)
IB 16 (3%) 17 (3%)
II 166 (31%) 157 (29%)
III 142 (26%) 175 (32%)
IV 193 (36%) 162 (30%)
Bulky disease 272 (50%) 261 (48%)
B symptoms 238 (44%) 251 (46%)
Elevated lactate dehydrogenase 350 (65%) 351 (65%)
International prognostic index score
0 43 (8%) 40 (7%)
1 117 (22%) 116 (21%)
2 143 (26%) 163 (30%)
3 143 (26%) 136 (25%)
4 79 (15%) 75 (14%)
5 15 (3%) 10 (2%)
Phenotype 275 285
Germinal centre 145 (53%) 144 (51%)
Non-germinal centre 130 (47%) 141 (49%)
Proliferation rate 262 265
MIB1 ≥80% 127 (48%) 106 (40%)
MIB1 ≥90% 71 (27%) 49 (18%)
P53 overexpression 136/299 (45%) 171/309 (55%)
MYC rearrangement 16/175 (9%) 20/184 (11%)
BCL2 translocation 41/178 (23%) 49/190 (26%)
BCL6 rearrangement 32/176 (18%) 44/185 (24%)
MYC plus BCL2 (double-hit abnormality) 5/172 (3%) 11/182 (6%)
Other disease types diagnosed at central review 12 12
Burkitt’s lymphoma 0 1 (<1%)
B-cell chronic lymphocytic leukaemia 1 (<1%) 3 (<1%)
Follicular lymphoma 4 (<1%) 4 (<1%)
Marginal zone lymphoma 2 (<1%) 0
B-cell non-Hodgkin lymphoma not otherwise classiﬁ ed 0 2 (<1%)
Indolent lymphoma not otherwise classiﬁ ed 1 (<1%) 0
Hodgkin’s lymphoma 2 (<1%) 0
Lymphocyte predominant Hodgkin’s lymphoma 1 (<1%) 0
Peripheral T-cell lymphoma 1 (<1%) 1 (<1%)
No lymphoma 0 1 (<1%)
Data are number, number (%), or n/N (%). R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisolone every 21 days. R-CHOP-14=cycles of rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisolone every 14 days. 
Table 1: Baseline characteristics of patients
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was to detect an improvement of 8% (from 70% to 78%) 
with R-CHOP-14. With 5% signiﬁ cance and 90% power 
(two-sided), a total of 330 OS events were needed. The 
plan was to randomly assign a total of 1080 patients 
over 3 years. The required number of OS events was 
expected to occur 1 year after the last patient was 
randomly assigned.
The total number of OS events reported (n=182) 1 year 
after the completion of recruitment was much lower 
than expected; therefore, the statistical plan was 
amended on the basis of the estimates from the com-
bined groups without formal comparisons between 
groups: the estimated 2-year OS in the R-CHOP-21 
group was about 75–80%, and a total of 233 OS events 
would be needed to detect a 7–8% diﬀ erence in OS with 
5% signiﬁ cance level and 90% power. The amendment 
was approved by the steering committee and indepen-
dent data monitoring committee.
OS was calculated from the date of randomisation until 
the date of death from any cause; patients still alive were 
censored at the date they were last known to be alive.
PFS was calculated from the date of randomisation to 
the date of ﬁ rst appearance of disease progression, 
relapse, or death from any cause; patients alive without 
progression or relapse were censored at the date they 
were last known to be alive.
Response was assessed by the local treating physician 
as complete response (CR), unconﬁ rmed complete re-
sponse (CRu), partial response (PR), stable disease, or 
progressive disease (PD) in accordance with the 
International Workshop Standardized Response Criteria 
for Non-Hodgkin Lymphoma.17 The severity of adverse 
events was deﬁ ned according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (NCI-CTCAE, version 3.0).
The log-rank test was used to compare the Kaplan-
Meier curves for OS and PFS. The χ² test for interaction 
or trend was used to ascertain the diﬀ erences in the 
beneﬁ ts of R-CHOP-14 in diﬀ erent patients subgrouped 
according to baseline characteristics. The response 
achieved during treatment was compared by use of the 
Mann-Whitney test. Patients who received at least one 
cycle of assigned protocol treatment were included in the 
safety analyses. Cox regression model was applied in the 
prognostic analyses. All p values were two-sided.
This study is registered, number ISCRTN 16017947.
Role of the funding source
The trial sponsor (University College London) was 
responsible for randomisation, data gathering, entry, and 
validation, monitoring procedures, reporting of serious 
adverse events, organisation of central patho logical 
review, liaison with investigators, statistical analysis, and 
production of the report. Chugai Pharma ceutical had no 
role in study design, data gathering or interpretation, 
statistical analysis, or the writing of the report. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
From March, 2005, to November, 2008, 1080 patients 
were randomly assigned to treatment (540 in each 
group). Nine patients did not commence treatment due 
to consent withdrawal, illness, or death (ﬁ gure 1). Base-
line characteristics of patients, including IPI, were well 
balanced between groups (table 1). 937 patients (459 in 
R-CHOP-21 group and 478 in R-CHOP-14 group) had 
central pathology review; up to 560 patients (275 and 285, 
respectively) were assessable for molecular characteristics 
and the groups were also well balanced (table 1).
422 (78%) of 540 patients completed all eight cycles of 
R-CHOP-21 and 476 (88%) of 540 completed per-protocol 
R-CHOP-14; 91% in each group (489 in R-CHOP-21 group 
and 494 in R-CHOP-14 group) completed at least six 
cycles. Table 2 shows that the percentages for the median 
total dose received for each drug by treatment group were 
similar in the R-CHOP-21 and R-CHOP-14 groups; the 
median dose intensities achieved for each drug by 
treatment group were also similar with the exception 
of vincristine. In the R-CHOP-21 group, 420 (78%), 
Median total dose received/
planned total dose (mg)
Median dose intensity achieved/
planned dose intensity 
(mg/m² per day)
R-CHOP-21 R-CHOP-14 R-CHOP-21 R-CHOP-14
Cyclosphosphamide 98% (88–100) 100% (97–100) 96% (91–100) 98% (92–100)
Doxorubicin 99% (87–100) 100% (97–100) 96% (91–100) 98% (92–100)
Vincristine 100% (75–100) 100% (83–100) 71% (65–75) 98%* (84–100)
Prednisolone 99% (90–102) 100% (100–100) 98% (92–100) 99%* (92–100)
Rituximab 98% (87–100) 99% (94–100) 96% (91–100) 97% (90–100)
Data are % (IQR). R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone 
every 21 days. R-CHOP-14=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone 
every 14 days. *Vincristine and prednisolone were ﬁ xed doses and not calculated according to body surface area in the 
R-CHOP-14 group; therefore, median dose intensities were calculated in mg/day.
Table 2: Total dose received by patients and dose intensity achieved
R-CHOP-21 
(n=500)
R-CHOP-14 
(n=502)
Diﬀ erence 
(95% CI)*
p value
Complete response 243 (49%) 207 (41%) ·· ··
Unconﬁ rmed complete response 70 (14%) 87 (17%) ·· ··
Partial response 126 (25%) 162 (32%) ·· ··
Stable disease 31 (6%) 25 (5%) ·· ··
Progressive disease or relapse 30 (6%) 21 (4%) ·· ··
Complete response or unconﬁ rmed 
complete response
313 (63%) 292 (58%) 5% (–2 to 10) 0·1830
Overall response rate 439 (88%) 456 (91%) –3% (–7 to 1) 0·1223
Data are number (%), unless otherwise indicated. R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisolone every 21 days. R-CHOP-14=cycles of rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisolone every 14 days. *Only reported for secondary endpoints.
Table 3: Response to treatment
Articles
www.thelancet.com   Vol 381   May 25, 2013 1821
417 (77%), 439 (81%), 371 (69%), and 432 (80%) patients 
received at least 80% of the planned total dose of 
cyclosphosphamide, doxorubicin, prednisolone, vincris-
tine, and rituximab, respectively. In the R-CHOP-14 group, 
497 (92%), 494 (91%), 500 (93%), 444 (82%), and 469 (87%) 
patients received at least 80% of the planned total dose of 
cyclosphosphamide, doxo rubicin, prednisolone, vincris-
tine, and rituximab, respec tively. The median dose inten-
sity for individual drugs in the R-CHOP-14 group relative 
to the R-CHOP-21 group was 152% for cyclophosphamide, 
152% for doxorubicin, 148% for vincristine, 191% for 
prednisolone, and 151% for rituximab.
All 540 patients in the R-CHOP-14 group received G-CSF 
as per-protocol treatment; 293 (54%) of 540 pa tients in 
the R-CHOP-21 group were given G-CSF as secondary 
prophylaxis. 54 (10%) patients in the R-CHOP-21 group 
and 51 (9%) in the R-CHOP-14 group underwent radio-
therapy after chemotherapy.
Response after four cycles was assessable in 981 (91%) of 
1080 patients, with CR or CRu documented in 169 (34%) 
of 490 patients in the R-CHOP-21 group and 159 (32%) of 
491 in the R-CHOP-14 group. End-of-treat ment response 
was assessable in 1002 (93%) patients who received at 
least one cycle of treatment. CR or CRu at the end of 
treatment, as assessed by use of CT scanning, was noted 
in 63% of patients in the R-CHOP-21 group and 58% of 
those receiving R-CHOP-14 (p=0·1830; table 3). The diﬀ er-
ence in overall response rate between treatment groups 
was not signiﬁ cant (88% patients in R-CHOP-21 group vs 
91% in R-CHOP-14 group; p=0·1223; table 3).
At the time of the analysis, median follow-up was 
46 months (IQR 35–57). The 2-year PFS was 74·8% 
(95% CI 71·0–78·4) in the R-CHOP-21 group and 75·4% 
(71·8–79·1) in the R-CHOP-14 group (ﬁ gure 2A). 14 (1%) 
CNS relapses (eight in R-CHOP-21 group and six in 
R-CHOP-14 group) were reported, with isolated recur-
rences in seven of these patients (four [<1%] in the 
R-CHOP-21 group and three [<1%] in the R-CHOP-14 
group). The 2-year OS was 80·8% (77·5–84·2) in the 
R-CHOP-21 group and 82·7% (79·5–85·9) in the 
R-CHOP-14 group (ﬁ gure 2B).
By use of the Cox regression model for prognostic 
factor analysis with both groups combined, a higher IPI 
was associated with worse OS: IPI 4 or 5 versus 0–3 
(hazard ratio [HR] 2·15, 95% CI 1·63–2·83; p<0·0001). 
Multi variate Cox regression analysis of individual prog-
nostic factors, including age as a continuous variable, 
showed that age (p<0·0001), stage (p=0·0007), WHO 
performance status (p<0·0001), raised lactate dehydro-
genase con centration (p=0·0007), and presence of 
B symptoms (p=0·0486) were independent prognostic 
factors (p<0·05 deemed signiﬁ cant).
According to the results of the molecular analysis, MYC 
rearrangement (n=36) was prognostic for OS (2-year OS, 
MYC-rearranged 75%, 95% CI 60·7–89·0, vs MYC -
normal 85%, 80·7–88·6; HR 2·08, 1·15–3·78; p=0·0160) 
and when adjusted for age, sex, stage, presence of 
B symptoms, bulky disease, WHO performance status, 
and raised lactate dehydrogenase concentrations, survival 
was non-sig niﬁ cantly worse (1·71, 0·92–3·18; p=0·0875). 
The so-called double-hit mutation (both MYC and BCL2 
re arrange ments; n=16) was non-signiﬁ cantly prognostic 
for 2-year OS (double-hit 63%, 38·8–86·1, vs no double-
hit 84%, 80·5–88·3; 2·24, 95% CI 0·98–5·17; p=0·0575), 
which was main tained in the multivariate analysis 
(2·03, 0·87–4·73; p=0·1023). No other assess ments with 
immuno histochemistry or FISH were prog nostic for 
2-year OS, including germinal centre versus non-
germinal centre phenotype, MIB1, P53 expression, and 
BCL6 and BCL2 rearrange ments (appendix pp 1–4).
In a planned subgroup analysis, no factor was pre-
dictive for a survival beneﬁ t of R-CHOP-14 versus 
R-CHOP-21 (ﬁ gures 3, 4) including age, sex, stage, 
presence of B symptoms, bulky disease, WHO perfor-
mance status, raised lactate dehydrogenase concen-
trations, or features of aggressive disease such as high 
proliferation rate and high IPI, although the probability 
of survival was non-signiﬁ cantly in favour of R-CHOP-21 
in the subgroup with MIB1 of at least 90% (HR 2·09, 
95% CI 0·87–5·00, p=0·06). None of the gene abnor-
malities detected by use of FISH, including MYC 
rearrangement and the double-hit mutation status, or 
Figure 2: Progression-free survival (A) and overall survival (B) according to treatment
R-CHOP-14=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 14 days. 
R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days.
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phenotype (germinal centre or non-germinal centre) 
were predictive for beneﬁ t in R-CHOP-14 or R-CHOP-21.
255 people died, 134 in the R-CHOP-21 group 
(85 lymphoma-related, three treatment-related, nine 
secon dary malignancies, eight cardiac causes, 25 other 
illnesses, and four unknown causes) and 121 in the 
R-CHOP-14 group (79 lymphoma-related, nine treat-
ment-related, six secondary malignancies, six cardiac 
causes, 17 other illnesses, and four unknown causes; 
appendix p 5). All cardiac deaths occurred at least 
3 months after completion of treatment.
Frequencies of grade 3 or 4 neutropenia and febrile 
neutropenia were signiﬁ cantly higher with R-CHOP-21, 
probably due to the reduced use of G-CSF, whereas 
grade 3 or 4 thrombocytopenia was signiﬁ cantly higher in 
the R-CHOP-14 group (table 4). Of 422 patients in the 
R-CHOP-21 group who received eight cycles of treat ment, 
303 (72%) had a toxicity of grade 3 or greater from cycles 
one to eight, and 282 (67%) from cycles one to six, and 
21 (5%) from cycles seven to eight. 13 grade 5 toxicities 
were reported—neutropenic sepsis (one in R-CHOP-21 
group and one in R-CHOP-14 group), non-neutropenic 
sepsis (one and two, respectively), suicide (two in 
R-CHOP-21 group), renal failure (one in R-CHOP-14 
group), multi organ failure (one in R-CHOP-14 group), 
and not speciﬁ ed (four in R-CHOP-14 group).
Discussion
The primary endpoint of superior overall survival with 
R-CHOP-14 compared with R-CHOP-21 was not met, 
and R-CHOP-14 did not improve response rates, PFS, or 
safety despite preservation of dose intensity. The two 
regimens were similar in all eﬃ  cacy endpoints; however, 
the study was not powered to detect non-inferiority.
Similar results were presented at the 2012 American 
Society of Clinical Oncology conference by the GELA 
group from their study of 602 patients aged 60–80 years.18 
Patients were randomly assigned to eight cycles of 
either R-CHOP-14 or R-CHOP-21; however, G-CSF was 
adminis tered at the investigator’s discretion in both 
groups, resulting in a reduced dose intensity of doxo-
rubicin and cyclophos phamide in the R-CHOP-14 group 
compared with the dose intensity in our study, and that 
of the original German reports.4,6 The smaller GELA 
study was powered for superiority and the results showed 
no diﬀ erence in event-free survival, PFS, OS, response 
rate, or safety, supporting our ﬁ ndings.18 Of note, in 
routine clinical practice many patients now receive only 
six cycles of R-CHOP.
In our study, toxicities in the two groups were similar; 
R-CHOP-14 was associated with signiﬁ cantly more 
Figure 3: Analysis of prognostic factors for overall survival
Data are number, unless otherwise indicated. R-CHOP-14=cycles of rituximab 
plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 
14 days. R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisolone every 21 days. df=degrees of freedom.
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thrombocytopenia than was R-CHOP-21, but less neutro-
penia because of G-CSF primary prophylaxis. Treatment-
related deaths were numerically higher in the R-CHOP-14 
group (nine vs three); however, the diﬀ erence was not 
signiﬁ cant (p=0·082).
Few studies have shown a beneﬁ t of dose intensiﬁ -
cation with incorporation of rituximab versus standard 
rituximab–chemotherapy combinations, despite the 
targeting of high-risk populations.19–22 In a younger popu-
lation, improved eﬃ  cacy with the addition of etoposide to 
CHOP-14 was lost when combined with rituximab.13 
First-line high-dose chemotherapy plus rituximab 
followed by autologous stem-cell transplant has also not 
improved outcomes compared with rituximab–chemo-
therapy alone.23,24 By contrast, in a study by the GELA 
group,25 a signiﬁ cant survival advantage was reported 
with R-ACVBP compared with R-CHOP-21 in 380 young 
patients with low-risk or low-intermediate-risk disease. 
After a median follow-up of 44 months, the 3-year event-
free survival was 81% in the R-ACVBP group compared 
with 67% with R-CHOP-21, and 3-year PFS was 87% and 
73%, respectively. However, this improve ment was asso-
ciated with a three times increase in serious adverse 
events in the experimental group and febrile neutropenia 
in 38% of patients, despite G-CSF prophyl axis, versus 7% 
with R-CHOP-21. In the Comment accompanying this 
GELA trial, the recom mendation was that R-ACVBP 
should not be oﬀ ered routinely until high-risk groups 
can be accurately iden tiﬁ ed to justify the additional 
toxicity.26 Of note, the 2-year PFS was 80% in patients in 
our study who were younger than 60 years with IPI 0–2 
receiving R-CHOP-21.
Molecular features such as high proliferation index, P53 
deletion, and BCL2, MYC, and BCL6 rearrange ments 
have previously been identiﬁ ed as poor prognostic mar-
kers in retrospective or small series.16,27–29 In this study, 
only MYC rearrangement (10% of patients) was a poor 
prognostic marker in the univariate analysis but was not 
predictive for beneﬁ t of R-CHOP-14. Double-hit diﬀ use 
large B-cell lymphomas are known to have a worse 
prognosis,16,30–32 and although, in our study, this group of 
patients had poorer survival, in the multivariate analysis 
the diﬀ erence was not signiﬁ cant and the eﬀ ect of double-
hit rearrangements might have been over estimated in 
previous retrospective studies. Molecular analysis showed 
no other poor prognostic subgroup or a cohort that 
beneﬁ ted from R-CHOP-14. This ﬁ nding was also 
reﬂ ected in the absence of sig niﬁ cantly improved out-
comes from R-CHOP-14 in patients with high IPI. With 
respect to the cell of origin, germinal centre diﬀ use large 
B-cell lymphoma has also been reported to have a better 
Figure 4: Analysis of prognostic factors for progression-free survival
Data are number, unless otherwise indicated. R-CHOP-14=cycles of rituximab 
plus cyclophosphamide, doxorubicin, vincristine, and prednisolone every 
14 days. R-CHOP-21=cycles of rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisolone every 21 days. df=degrees of freedom.
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prognosis than does the non-germinal centre type;27,33–35 
although a diﬀ erence was not noted in our study, the Hans 
criteria method for determination of the cell of origin is 
inferior to gene expression proﬁ ling. Never theless, while 
the tissue used was of suitable quality for deﬁ nition of the 
immunophenotype in only 50% of cases, this analysis is 
one of the largest undertaken within a prospective trial.
R-CHOP-14 has eﬃ  cacy in patients with diﬀ use large 
B-cell lymphoma (panel). However, it is not superior to 
standard R-CHOP-21 and this trial was not powered 
to show non-inferiority of R-CHOP-14 to R-CHOP-21; 
therefore, R-CHOP-21 remains the standard reference 
regimen. Results of the biomarker analysis and clinical 
stratiﬁ  cation did not identify a subgroup of patients who 
would beneﬁ t from a more intensiﬁ ed regimen.
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chemotherapy”, and “rituximab”.
The beneﬁ t of combination rituximab and CHOP-1412,13 (cycles of rituximab plus 
cyclophosphamide, doxorubicin, vincristine, and prednisolone every 14 days) or CHOP-21 
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received dose reductions in the R-CHOP-14 group.18 R-CHOP-14 and R-CHOP-21 have not 
been compared in a large cohort study with inclusion of all patient and disease subgroups, 
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Interpretation
Reports of studies have consistently shown the beneﬁ t of adding the anti-CD20 
monoclonal antibody rituximab to CHOP in previously untreated diﬀ use large B-cell 
lymphoma, irrespective of the population assessed. Before the introduction of rituximab 
into the routine care of patients with diﬀ use large B-cell lymphoma, the ﬁ ndings of several 
reports showed a beneﬁ t of dose-intensiﬁ ed regimens compared with standard CHOP, 
including CHOP-14, rather than CHOP-21. The results of our randomised, phase 3 study of 
the comparison of R-CHOP-14 with R-CHOP-21 in 1080 patients from all prognostic groups 
showed that R-CHOP-14 is not superior to R-CHOP-21; therefore, in the era of rituximab, 
R-CHOP-21 remains the standard ﬁ rst-line treatment for diﬀ use large B-cell lymphoma.
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